NUVALENT INC's ticker is and the CUSIP is 670703107. A total of 55 filers reported holding NUVALENT INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,877,507 | +43.6% | 40,842 | +31.8% | 0.00% | 0.0% |
| Q2 2023 | $1,307,017 | -9.9% | 30,994 | -44.3% | 0.00% | 0.0% |
| Q1 2023 | $1,451,413 | +121.0% | 55,631 | +152.3% | 0.00% | 0.0% |
| Q4 2022 | $656,738 | +4278.3% | 22,053 | +2723.7% | 0.00% | – |
| Q3 2022 | $15,000 | -42.3% | 781 | -59.0% | 0.00% | – |
| Q2 2022 | $26,000 | +13.0% | 1,904 | +16.0% | 0.00% | – |
| Q1 2022 | $23,000 | -70.1% | 1,642 | -59.4% | 0.00% | – |
| Q4 2021 | $77,000 | +175.0% | 4,046 | +225.2% | 0.00% | – |
| Q3 2021 | $28,000 | – | 1,244 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 19,991,024 | $918,987,373 | 20.25% |
| Bain Capital Life Sciences Investors, LLC | 3,577,267 | $164,446,964 | 18.39% |
| Fairmount Funds Management LLC | 2,451,819 | $112,710,119 | 13.56% |
| Paradigm Biocapital Advisors LP | 1,638,147 | $75,305,618 | 5.11% |
| COMMODORE CAPITAL LP | 828,778 | $38,098,925 | 4.45% |
| Perceptive Advisors | 2,463,451 | $113,244,842 | 3.78% |
| Boxer Capital, LLC | 1,210,192 | $55,632,526 | 2.96% |
| Tri Locum Partners LP | 113,528 | $5,218,882 | 1.67% |
| Ikarian Capital, LLC | 278,034 | $12,781,224 | 1.54% |
| Ikarian Capital, LLC | 2,395 | $11,009,815 | 1.32% |